Efficacy of the 7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline derivative against infection caused by Leishmania amazonensis

INTRODUCTIONThe drugs currently available for leishmaniasis treatment have major limitations. METHODSIn vitro and in vivo studies were performed to evaluate the effect of a quinoline derivative, Hydraqui (7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline, against Leishmania amazonensis. In silico a...

Full description

Saved in:
Bibliographic Details
Published in:Revista da Sociedade Brasileira de Medicina Tropical 2020-01, Vol.53, p.e20200091-e20200091
Main Authors: Antinarelli, Luciana Maria Ribeiro, Souza, Marcus Vinicius Nora de, Coelho, Eduardo Antonio Ferraz, Lima, Wallace Pacienza, Coimbra, Elaine Soares
Format: Article
Language:English
Subjects:
Chemotherapy
Cutaneous leishmaniasis
Leishmania amazonensis
Quinoline
Short Communication
Toxicity
TROPICAL MEDICINE
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:INTRODUCTIONThe drugs currently available for leishmaniasis treatment have major limitations. METHODSIn vitro and in vivo studies were performed to evaluate the effect of a quinoline derivative, Hydraqui (7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline, against Leishmania amazonensis. In silico analyses of absorption, distribution, metabolism, excretion, and toxicity (ADMET) parameters were performed. RESULTSHydraqui showed significant in vitro anti-amastigote activity. Also, Hydraqui-treated mice exhibited high efficacy in lesion size (48.3%) and parasitic load (93.8%) reduction, did not cause hepatic and renal toxicity, and showed appropriate ADMET properties. CONCLUSIONSHydraqui presents a set of satisfactory criteria for its application as an antileishmanial agent.
ISSN:0037-8682
1678-9849
1678-9849
DOI:10.1590/0037-8682-0091-2020